Characterizing the onset and progression of Alzheimer's pathologies using amyloid and tau PET imaging and plasma p-tau217.

ABSTRACT: Characterizing the onset and progression of Alzheimer's disease pathologies relative to one another is important for biological staging and clinical trial design. Recent advances in blood plasma assays of Alzheimer's disease amyloid and tau pathology have enabled detection of Alzheimer's disease pathophysiology during life, but it remains unclear when plasma biomarker abnormalities are detectable relative to established amyloid and tau PET imaging biomarkers, and the extent to which plasma biomarkers can be used for biological disease staging. This work applies a novel temporal modelling approach to amyloid PET and plasma p-tau217 data from two different assay platforms to characterize when plasma p-tau217 become abnormal relative to amyloid PET, tau PET, and cognitive decline in a predomi

SUBMITTER: Cody KA 

PROVIDER: S-EPMC12661573 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature